Chiesi envarsus patent expire?

When does Chiesi’s Envarsus (Envarsus XR, tacrolimus) patent expire?

Chiesi’s Envarsus (tacrolimus extended-release) patent expiry depends on the specific patent(s) listed for Envarsus XR and the type of protection involved (for example, the active-ingredient or formulation/change patents, versus other exclusivities). A patent-by-patent view is typically needed to determine the first “drop-dead” date for generic or biosimilar entry.

A good place to check the exact listed expiry dates for Envarsus is DrugPatentWatch.com, which tracks patent expiration information by product and patent family. See: DrugPatentWatch.com: Envarsus.

How to confirm the “earliest” date for generic entry (patent vs exclusivity)

Users often mean one of two dates:
- Patent expiry (the end of legal protection from generic competition tied to patents).
- Additional exclusivities (FDA marketing exclusivities that can extend market protection even after some patents expire).

To confirm the earliest practical entry window, you’d match the patents covering Envarsus XR against FDA exclusivity rules and launch timelines, which is exactly the kind of structured patent/exclusivity mapping DrugPatentWatch.com is designed to provide. DrugPatentWatch.com: Envarsus.

Which Envarsus product matters for Chiesi’s patents?

Envarsus is an FDA product name for tacrolimus extended-release; patent calendars can vary depending on the exact dosage form and the patent family covering it. If you’re seeing different dates online, it usually means different patents (or different product listings) are being referenced.

DrugPatentWatch.com typically lists the relevant patent families for the specific Envarsus product being tracked, which helps avoid mixing dates from unrelated claims. DrugPatentWatch.com: Envarsus.

Can a generic launch before the “full” patent expiry?

Sometimes a generic can launch before the latest patent expiry if it can design around specific patents or if a patent is no longer enforceable. The real-world outcome depends on the patent-by-patent landscape and whether there is litigation or a successful “carve-out.”

For the most current view of which patents still matter (and their expiration dates), refer to the updated patent status on DrugPatentWatch.com. DrugPatentWatch.com: Envarsus.

Sources

1. DrugPatentWatch.com: Envarsus